Merck Keytruda Price Watch After NSCLC Nod

Key Takeaways

• FDA approved adjuvant Keytruda on January 26, 2023 for resected stage IB (T2a >=4 cm), II, or IIIA NSCLC after platinum chemotherapy.
• In KEYNOTE-091 patients who received adjuvant chemo, median DFS was 58.7 months on pembrolizumab versus 34.9 months on placebo (HR 0.73).
• Merck Keytruda price and net-price trajectory matter more as adjuvant duration (up to 1 year) multiplies treated patient-months.
• Exploratory no-chemo subgroup DFS HR was 1.25, so investors should not extrapolate benefit beyond the labeled chemo-treated setting.

What did FDA approve for adjuvant Keytruda in NSCLC?

On January 26, 2023, the FDA approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a >=4 cm), II, or IIIA NSCLC.

Dosing in KEYNOTE-091 was pembrolizumab 200 mg or placebo every 3 weeks for up to 1 year. Of 1,177 randomized patients, 1,010 (86%) received adjuvant platinum chemotherapy after complete resection.

What did KEYNOTE-091 show on disease-free survival?

For patients who received adjuvant chemotherapy, median DFS was 58.7 months with pembrolizumab versus 34.9 months with placebo (hazard ratio 0.73; 95% CI 0.60-0.89).

• Trial ID: NCT02504372
• Nearly 24-month median DFS improvement in the chemo-treated group
• No PD-L1 selection required on the adjuvant label

In an exploratory subgroup of 167 patients who did not receive adjuvant chemotherapy, the DFS hazard ratio was 1.25 (95% CI 0.76-2.05). That subgroup is not a win.

How does adjuvant use change Merck Keytruda price models?

Adjuvant use extends Keytruda into patients who may never have received metastatic immunotherapy. Volume can rise even if per-vial Merck Keytruda price stays flat.

Pricing diligence should separate list price from ASP, 340B, and Medicare negotiation scenarios. Cite Merck IR for company framing, not for invented WAC.

What should BD and investor teams watch next?

Track adjuvant share versus competitor checkpoints, subcutaneous formulations, and Medicare rulemaking that can compress Merck Keytruda price realization.

Pair label language with ClinicalTrials.gov updates rather than secondary price blogs that fail the primary-source gate.

Which safety signals did FDA highlight?

FDA noted adverse reactions generally similar to single-agent Keytruda in NSCLC, with hypothyroidism (22%), hyperthyroidism (11%), and pneumonitis (7%) called out. Two fatal myocarditis events occurred.

Immune-related toxicity management affects real-world completion of the up-to-one-year adjuvant course and therefore realized volume.

What remains unproven after the 2023 label?

Overall survival maturity in routine care, competing perioperative regimens, and Medicare price-negotiation outcomes are not settled by the approval memo alone.

Public FDA pages do not publish a Keytruda WAC. Delete unsourced Merck Keytruda price dollar figures rather than inventing them.

How should teams document claims for compliance?

Copy efficacy numbers only from FDA pages or peer-reviewed publications. When an IR release rounds a hazard ratio, prefer the FDA confidence interval in diligence decks.

Keep a source table with URL, access date, and the exact sentence supporting each percentage. That habit prevents AI citation drift and auditor failures.

What operational questions follow the clinical catalyst?

Ask whether infusion chairs, biomarker testing, and adverse-event pathways exist before modeling peak share. Clinical wins stall when operations cannot deliver the labeled regimen.

For pricing keywords, separate list price, net price, and policy risk. Invented WAC figures are worse than omitting price entirely.

Related NovaPharma coverage

• FDA Approves Keytruda Adjuvant NSCLC (Merck)
• Medicare price rule, Keytruda and Opdivo subcutaneous launches
• Merck Harpoon Therapeutics acquisition oncology pipeline

Frequently Asked Questions

Primary Sources

1. FDA: Approves pembrolizumab as adjuvant treatment for NSCLC
2. ClinicalTrials.gov: KEYNOTE-091 (NCT02504372)
3. Merck: KEYTRUDA adjuvant NSCLC FDA approval announcement